CVS Health says employers are showing more confidence in its pharmacy benefit services, as it rolls out new PBM tools

CVS Health is expanding its pharmacy benefit management toolkit for employer clients, saying new products and features are being rolled out as confidence in how PBMs handle drug spending and patient access rises. The company’s comments, reported by Yahoo Finance, were tied to a CVS Caremark survey in which employers indicated greater trust in pharmacy benefit managers to control costs while still enabling access to therapies that can be difficult to obtain.

PBMs, short for pharmacy benefit managers, act as intermediaries between drug manufacturers, pharmacies, employers or insurers, and patients. Their roles typically include negotiating drug pricing, administering pharmacy networks, handling pharmacy claims, and supporting utilization management programs that can influence which medications are used and under what conditions.

In its latest update, CVS Health framed the employer survey as evidence that its clients want solutions that balance cost management with continuity of care. The company said employers are increasingly relying on PBMs to manage drug costs and to help patients access complex treatments, positioning its Caremark platform as the operational layer for those services.

Alongside the trust data, CVS Caremark said it is rolling out new PBM tools. The company did not provide, in the reported account, a detailed breakdown of the specific tools’ mechanics, clinical coverage rules, or pricing changes. It also did not outline whether the tools are being deployed uniformly across all employer plans, or whether implementation varies by plan design, employer size, or geographic market.

What CVS Health did emphasize is the employer perspective. In the survey results described in the Yahoo Finance report, employers expressed higher confidence that PBMs can both help reduce drug spending and support access to treatments that may require special handling, higher clinical coordination, or additional steps such as prior authorization. Prior authorization is a common utilization management step in which a plan requires documentation from a clinician before approving certain medications.

The report also reflects a broader challenge facing PBMs: employers and plan sponsors are under pressure to moderate prescription drug costs without creating barriers to treatment. That pressure has increased in recent years as drug prices and utilization have remained major cost drivers for commercial health plans, and as lawmakers and regulators have scrutinized PBM practices related to pricing transparency and pharmacy reimbursement.

Within this environment, CVS’s emphasis on “trust” suggests the company is trying to differentiate on the employer-client relationship, not just on pricing. PBM contracts can be complex, and employers often evaluate PBMs based on total cost performance, member experience, administrative support, and how efficiently the PBM manages medication access and approvals.

Still, the current disclosure leaves open many operational questions. The company did not specify, in the account described by Yahoo Finance, whether the new tools focus more on utilization management automation, coverage administration, pharmacy network design, or member support workflows. It also did not disclose expected timelines for rollouts across employer portfolios, nor did it provide quantitative outcomes such as projected savings, changes in approval turnaround time, or impacts on utilization of higher-cost therapies.